EDWARD F. ROSENBERG, M.D., F.A.C.P.; DAVID A. KREVSKY, M.D.; B. M. KAGAN, M.D., F.A.C.P.
Gentisic acid, 2,5-dihydroxybenzoic acid, C6H3-(OH)2COOH, has been isolated from the urine of human subjects following administration of sodium salicylate.1
Recent studies have shown that this compound in dilute solutions exerts a powerful inhibiting effect on the action of the enzyme hyaluronidase. Salicylic acid solutions also inhibit the action of the enzyme, but only in relatively high concentrations.2
This action of gentisic acid stimulated research into the effectiveness of this compound as a therapeutic agent in rheumatic diseases. Studies reported by Meyer and Ragan3 suggested that one possible mechanism of pathogenesis in rheumatic diseases may be the breakdown of interfibrillar cement
EDWARD F. ROSENBERG, DAVID A. KREVSKY, B. M. KAGAN. LABORATORY AND CLINICAL EXPERIENCE WITH SODIUM GENTISATE IN RHEUMATIC DISEASE(LABORATORY AND CLINICAL EXPERIENCE WITH SODIUM GENTISATE IN RHEUMATIC DISEASE*). Ann Intern Med. 1952;36:1513–1519. doi: 10.7326/0003-4819-36-6-1513
Download citation file:
Published: Ann Intern Med. 1952;36(6):1513-1519.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use